The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The US Food and Drug Administration (FDA) has accepted for review the resubmitted supplemental Biologics License Application (sBLA) for Sanofi and Regeneron’s Dupixent (dupilumab) in chronic ...

Credit: wisely via Shutterstock. The US Food and Drug Administration (FDA) has accepted for review the resubmitted supplemental Biologics License Application (sBLA) for Sanofi and Regeneron’s Dupixent ...

But it takes about 3 months for Dupixent to be fully cleared from your system. But it’s possible that healthcare professionals may prescribe this drug off-label for other conditions.

Dupixent (dupilumab) is a prescription drug that’s used to treat certain inflammatory conditions. The drug comes as a solution for injection under the skin. How often you’ll receive a dose ...

The 108-week open-label extension period (Part C) to evaluate longer-term outcomes was recently completed. Results from the trial were published in The New England Journal of Medicine. Dupixent is ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...

These outcomes were maintained for up to one year in Part B of the study. Part C, a 108-week open-label extension period to assess longer-term outcomes, was recently completed. Developed using ...

Dupixent and Adbry are FDA approved only for the atopic dermatitis form of eczema. It is possible, however, that healthcare providers might also prescribe these medicines off-label for other types of ...